Novo Nordisk to acquire Akero Therapeutics for 47 billion USD plus potential milestone payment
Reuters
Oct 09
<a href="https://laohu8.com/S/NVO">Novo Nordisk</a> to acquire <a href="https://laohu8.com/S/AKRO">Akero Therapeutics</a> for 47 billion USD plus potential milestone payment
Novo Nordisk will acquire all outstanding shares of Akero Therapeutics at a price of $54 per share in cash, representing a total value of $4.7 billion at closing. Akero shareholders will also receive a non-transferable contingent value right $(CVR)$ for a potential additional payment of $6 per share in cash, totaling $0.5 billion, if US regulatory approval is obtained for efruxifermin $(EFX)$ in treating compensated cirrhosis due to MASH. The transaction, unanimously approved by Akero's Board of Directors, is expected to close around the turn of the year, subject to customary closing conditions. The deal is not expected to impact Novo Nordisk's 2025 operating profit outlook, though free cash flow for 2025 is expected to decrease by about $4 billion, and increased R&D costs are anticipated to reduce 2026 operating profit growth by approximately 3 percentage points. The transaction will be primarily debt financed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001132323-en) on October 09, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.